Background: The antibody reactivity against Epstein-Barr nuclear antigen-1 (EBNA-1), and 25-hydroxyvitamin D (25(OH)D) status have been associated with multiple sclerosis (MS) risk. Interaction between these two factors has been proposed. Objectives: The objective of this paper is to examine the association between antibody reactivity against EBNA-1 and five EBNA-1 domains, and the risk of MS, and to examine if these antibodies and 25(OH)D status interact regarding MS risk in prospectively collected blood samples. Methods: Antibody reactivity and 25(OH)D levels were measured using ELISAs in n = 192 MS cases and n = 384 matched controls. The risk of MS was analysed using matched logistic regression. Interaction on the additive scale was assessed. Results: The risk of MS increased across tertiles of antibody reactivity against EBNA-1, domain EBNA-1 402-502 , and domain EBNA-1 385-420 ; p trends < 0.001. In young individuals (below median age at sampling, < 26.4 years), these associations were stronger, and 25(OH)D levels correlated inversely to antibody reactivity against EBNA-1 and the EBNA-1 domains. No statistical interaction was found.
Introduction
Elevated antibody reactivity against Epstein-Barr nuclear antigen-1 (EBNA-1) is associated with an increased risk of multiple sclerosis (MS). 1 This has been shown in several studies using biobank samples collected before MS onset. [2] [3] [4] [5] [6] [7] The link between Epstein-Barr virus (EBV) and MS is supported by epidemiological data showing an increased risk of MS after infectious mononucleosis (IM). 1, 8 Antibodies against the EBNA-1 385-420 domain (amino acid number 385-420) have been associated with a higher risk of MS than antibodies against EBNA-1 measured with a commercial enzyme-linked immunosorbent assay (ELISA) in samples drawn after disease onset, but no prospective studies have been performed. 9, 10 High 25-hydroxyvitamin D (25(OH)D) levels have been associated with a decreased risk of MS, and this association seems stronger in younger individuals. 11, 12 According to the prevailing view on adult MS aetiology, pathological events start several years before clinical onset, probably during adolescence. 1, 13, 14 It has been suggested that 25(OH)D status during this period of life and EBV interact to influence MS risk. 15, 16 The aims of this nested case-control study on prospectively collected serum and plasma samples were to test the associations between MS and: (1) the antibody reactivity against EBNA-1 using a commercial ELISA; and (2) the antibody reactivity against five different EBNA-1 domains.
We also aimed to test if these associations were confounded by, or interacted statistically with, 25(OH)D status.
Materials and methods
The study was performed at Umeå University Hospital in northern Sweden. In a previous study on this material, we have outlined in detail the process of case identification, and have described the biobank cohorts from which the prospectively collected samples from MS cases and matched controls were drawn. 12 Briefly, we established a database of MS cases in 2009 by searching for MS and adjacent diagnoses using several sources, and this database was then cross-linked to two local biobank cohorts (the Northern Sweden Maternity Cohort (NSMC) containing blood samples drawn during early pregnancy, and the Northern Sweden Health and Disease Study cohort (NSHDS), which is a population-based health promoting project). Medical records were examined to ascertain that MS diagnostic criteria were fulfilled in all cases, 12 and that no symptom suggestive of MS had occurred before sampling. Controls were selected, matched for biobank, sex, age at sampling and date of sampling.
Laboratory methods
The immunoglobulin G (IgG) antibody reactivity against EBNA-1 was measured using a commercially available ELISA (Biotest, Dreieich, Germany) following the manufacturer's instructions, apart from not analysing the samples in duplicates due to a limited supply of serum and plasma. The recombinant EBNA-1 fragments (amino acids 1-90, 61-90, 402-502, 385-420, and 421-449) were generated and purified according to a previously described method. 9 To quantify the binding of IgG to these EBNA-1 fragments, an in-house ELISA was used. ELISA plates (Greiner Bio-one) were coated with 0.5 µg/ml of EBNA-1 fragments in phosphate-buffered saline (PBS) pH 7.4 (Gibco) for 24 hours at 6°C. The wells were washed once in PBS Tween 0.05% (Medicago) before blocking with bovine serum albumin (BSA) 2% (w/v) (Sigma Aldrich) PBS pH 7.4 Tween 0.05% (Calbiochem) for one hour and washed four times with PBS Tween 0.05%. Serum samples were diluted 1:200 in BSA 1% PBS pH 7.4 Tween 0.05% and incubated for 1.5 hours at room temperature. After washing four times with PBS Tween 0.05%, peroxidase-labelled anti-human IgG (Sigma Aldrich), diluted 1:30,000 in BSA 1% PBS pH 7.4 Tween 0.05%, was added and incubated for one hour at room temperature. After washing the wells four times, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) substrate (Roche Diagnostics) was added and incubated for 30 minutes at room temperature. The reaction was stopped with 220 mM oxalic acid (Sigma Aldrich) and the OD 405nm was read on a Synergy Multi-Mode micro plate reader (Bio-Tek). All analyses were performed blind and in duplicate. The antibody reactivity of the samples was expressed in arbitrary units (AU) as a percentage of the absorbance of the positive control. The median (range) interassay coefficient of variation (CV) of the in-house ELISAs was 11% (8.2-15%), and the median (range) intra-assay CV was 2.6% (1.6-3.0%). Levels of 25(OH)D were measured in the same subjects for another study, using a commercially available ELISA (Immundiagnostik AG, Bensheim, Germany) following the manufacturer's instructions. 12 
Statistical analyses
Statistical analyses were performed using SPSS ver. 19.0. The risk of MS was estimated using tertiles (pre-defined) 2 of antibody reactivity against EBNA-1 and the EBNA-1 domains. Matched logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of MS by antibody reactivity tertiles, and the chi square test was used to examine trends over tertiles. To search for possible confounding, we added 25(OH)D status dichotomised (< 75 nmol/l vs. ≥ 75 nmol/l) to multivariable analyses, as levels ≥ 75 nmol/l were associated with a lower risk of MS in this material. 12 Interaction between the antibody reactivity against EBNA-1, the EBNA-1 domains (dichotomised at median) and 25(OH)D levels (dichotomised at 75 nmol/l) on the additive scale was assessed as described elsewhere. 17 The lowest antibody reactivity category among subjects with 25(OH)D levels ≥75 nmol/l was used as the reference category, since this combination would yield the lowest risk of MS based on earlier publications. 2, 11, 12 Pearson's correlation coefficient (r) was used to test for correlations between continuous variables. Probability is denoted by p.
Results
A total of n = 192 samples from MS cases, collected a median nine years (range two months to 32 years) before disease onset, were identified. 12 When analysing all subjects, there was an increasing risk of MS across tertiles of antibody reactivity against EBNA-1 and two of the EBNA-1 domains (EBNA-1 402-502 and 385-420 ), p for trend for all three < 0.001 (Figure and Supplementary Table 1 ). There were no correlations between 25(OH)D levels and antibody reactivity against EBNA-1 or any of the EBNA-1 domains among cases or controls, and addition of 25(OH)D status dichotomised (< 75 nmol/l vs. ≥75 nmol/l) to multivariable analyses did not alter the ORs or 95% CIs (Supplementary Table 1 ).
In the subgroup of young individuals (< 26.4 years old, below median age at sampling, n = 96 cases and n = 192 controls), the associations between the antibody reactivity against the EBNA-1 domains and the risk of MS were slightly more pronounced compared to when all subjects were analysed (Figure and Supplementary Table 2 ). Addition of 25(OH)D status dichotomised (< 75 nmol/l vs. ≥ 75 nmol/l) to multivariable analyses did not alter the ORs or 95% CIs (Supplementary Table 2 ). In this subgroup of cases and controls there were negative correlations between 25(OH)D levels and the antibody reactivity against EBNA-1 (r = −0.13; p = 0.03), the EBNA-1 402-502 domain (r = −0.13; p = 0.03), and the EBNA-1 385-420 domain (r = −0.14; p = 0.02). These correlations were even more pronounced in subjects aged < 20 years (n = 58), for EBNA-1 (r = −0.35; p < 0.01), for the EBNA-1 402-502 domain (r = −0.29; p = 0.03), and for the EBNA-1 385-420 domain (r = −0.29, p = 0.03).
No signs of statistical interaction were found (Supplementary Table 3 ).
Discussion
In this paper we have demonstrated that increased antibody reactivity against EBNA-1, and especially to a sub-unit of this protein containing the amino acids 385-420, in prospectively collected blood samples, were associated with a four-fold increased risk of MS. No signs of confounding by 25(OH)D status were found, which confirms the findings from one earlier report. 4 We did not observe any signs of statistical interaction between 25(OH)D and antibody reactivity. However, among young subjects, there was a weak negative correlation between levels of 25(OH)D and antibody reactivity against EBNA-1, the EBNA-1 402-502 domain, and the EBNA-1 385-420 domain, indicating that higher 25(OH)D levels may be associated with lower antibody reactivity against EBNA-1.
EBV infection has been suggested as one of the causal agents in MS aetiopathogenesis, since: (1) a history of IM is associated with an increased risk of MS; (2) the small proportion of EBV seronegative adults have virtually no risk of acquiring MS; and (3) numerous studies have shown an association between EBV and MS with an increased risk for MS with higher antibody reactivity against EBV proteins, particularly EBNA-1. 1, 8, 18 It has been suggested that the immune response against EBV during seroconversion might be influenced by age, genetic susceptibility and vitamin D status. 1, 16 In previous similar studies, EBNA-1 antibody reactivity and vitamin D status have been shown to be statistically independent risk factors of MS. 4, 19 However, a record linkage study has shown that there was a statistical interaction between IM prevalence and ultraviolet B (UVB) radiation, and that these two risk factors could explain 72% of the variance of the MS prevalence across England. 15 Further support for a possible aetiological interplay between these two risk factors was found in the subgroup of young (< 26.4 years old) individuals in the present study, in whom weak but significant associations between 25(OH)D levels and antibody reactivity against EBNA-1, and the EBNA-1 domains most specific for MS, were present. This association was most pronounced if the youngest (< 20 years old) subjects were selected. The fact that both risk factors are associated with a more pronounced effect on MS risk in young individuals argues that the functional interaction, if one indeed exists, is likely to occur at a younger age. 11, 16 Possible mechanisms for this putative link between 25(OH) D and EBV regarding MS aetiology could include immune modulation by vitamin D with higher regulatory T-cell activity, which may decrease the risk of IM in subjects with high 25(OH)D levels, 20, 21 or 1,25-dihydroxyvitamin D 3dependent attenuation of the proliferation and cytokine secretion by EBNA-1-specific T-cells. 22 The association between MS risk and EBV serology was further strengthened in this study and has been discussed previously. 1, 2, 9 This association was stronger for the EBNA-1 385-420 fragment than for the commercial EBNA-1 assay, especially in the younger subgroup (Figure) . This argues that this domain of EBNA-1 is of particular interest regarding MS aetiology. As discussed in a previous paper, 9 molecular mimicry between EBNA-1 and central nervous system (CNS) antigens has been suggested as a possible explanation for the association between EBNA-1 and MS. While it is possible that the EBNA-1 385-420 fragment resembles a structure in the CNS, 9 published data from cerebrospinal fluid studies have failed to demonstrate an intrathecal immune response suggestive of EBNA-1-induced molecular mimicry. 23, 24 This study suffers from some drawbacks, such as the unknown time lapse between EBV seroconversion and blood sampling which might confound serological studies on EBV and MS risk, and the fact that the correlation between 25(OH)D and EBNA-1 antibody reactivity was found only among the few young subjects. The interaction analyses would have ideally been performed on young subjects only; however, this was not possible as too few in this subgroup had 25(OH)D levels ≥ 75 nmol/l. This idea is also supported by the already mentioned finding of an interaction between UVB radiation and IM -a disease of adolescents in the Western world. 1, 15 In fact, there is growing evidence suggesting that the bulk of an individual's MS risk is established somewhere between peri-, or even prenatally, up to early adulthood, and the MS risk factors are probably best studied during this time period. 12, [25] [26] [27] [28] During this time period factors associated with MS risk such as EBV, vitamin D and smoking may act through epigenetic or other pathways to influence MS risk, and our study design and case-control cohort did not allow for proper investigation of these mechanisms. 25, 29 In summary, we have demonstrated an association between antibodies against EBNA-1, especially the EBNA-1 385-420 domain, and MS risk. We have also shown a weak negative correlation between 25(OH)D levels and EBNA-1 antibody reactivity in young subjects. This adds important information to the ongoing mapping of MS aetiology and points towards the time of primary EBV infection as being a key time point. Further research should focus on the time window at EBV seroconversion to establish whether 25(OH)D status influences the immune response against EBV and the risk of MS. The ideal cohort for this would be a cohort of subjects < 20 years old with higher 25(OH)D levels, which might be difficult to find in northern Sweden because of low levels of ambient UVB radiation.
